Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies
Setback Hitting Plans For Big And Small Companies
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
